Placental Growth and Adverse Pregnancy Outcomes
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Women's Studies |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Reproductive |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/19/2017 |
| Start Date: | November 2009 |
| End Date: | June 2016 |
Placental Growth and Maternal Serum Biomarkers in the Prediction of Adverse Pregnancy Outcome
The purpose of this study to determine if measurement of maternal serum biomarkers and
evaluation of the placenta by ultrasound can improve prediction of adverse pregnancy
outcomes.
evaluation of the placenta by ultrasound can improve prediction of adverse pregnancy
outcomes.
The placenta is known to play a vital role in maintaining a healthy pregnancy. Placental
dysfunction is believed to be a driving factor in a variety of adverse obstetric outcomes,
including fetal growth restriction and preeclampsia. Advances in 3D ultrasound have allowed
for measurement of placental volumes during pregnancy. It may be that quantitative assessment
of early placental growth can help identify pregnancies at risk for adverse outcome.
Furthermore, various novel serum analytes have been proposed as predictors of adverse
outcome. The investigators seek to prospectively measure placental volume and diameter at
11-14 weeks and 18-24 weeks to determine if placental growth can predict adverse outcome. In
addition, the investigators seek to investigate the relationship between placental growth and
serum levels of various biomarkers to see if improved detection of adverse outcome can be
achieved.
dysfunction is believed to be a driving factor in a variety of adverse obstetric outcomes,
including fetal growth restriction and preeclampsia. Advances in 3D ultrasound have allowed
for measurement of placental volumes during pregnancy. It may be that quantitative assessment
of early placental growth can help identify pregnancies at risk for adverse outcome.
Furthermore, various novel serum analytes have been proposed as predictors of adverse
outcome. The investigators seek to prospectively measure placental volume and diameter at
11-14 weeks and 18-24 weeks to determine if placental growth can predict adverse outcome. In
addition, the investigators seek to investigate the relationship between placental growth and
serum levels of various biomarkers to see if improved detection of adverse outcome can be
achieved.
Inclusion Criteria:
- All singleton gestations presenting for Sequential Screen testing at HUP
- patients competent to provide verbal informed consent
Exclusion Criteria:
- Multiple gestations
- patients not competent to provide informed consent
- patients found to be too late for the Sequential Screen
- pregnancy losses 20 weeks gestation
- major fetal anomalies
- patient delivering outside of the UPHS
We found this trial at
1
site
Click here to add this to my saved trials
